Analyst Price Target is $2.32
▲ +660.66% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Cara Therapeutics in the last 3 months. The average price target is $2.32, with a high forecast of $5.00 and a low forecast of $1.00. The average price target represents a 660.66% upside from the last price of $0.31.
Current Consensus is
Hold
The current consensus among 5 contributing investment analysts is to hold stock in Cara Therapeutics. This rating has held steady since May 2024, when it changed from a Moderate Buy consensus rating.
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Read More
